This finding suggests that the potential application of GGCT inhibitors in the treatment of comorbid conditions warrants further exploration—by restoring glutathione levels, alleviating oxidative damage in vascular cells, and improving pancreatic β-cell function in T2D patients, given that oxidative stress is a major cause of β-cell apoptosis (Dinić et al., 2022). The gene discussed is GGCT; the disease is type 2 diabetes mellitus.